Previous 10 |
Dosing is underway in a Phase 1b clinical trial evaluating Denali Therapeutics' (NASDAQ: DNLI ) DNL747 in Alzheimer's disease patients. The primary objectives are safety and biomarker data which will inform future studies. More news on: Denali Therapeutics, Inc., Sanofi, Healthcare st...
SOUTH SAN FRANCISCO, Calif., Feb. 15, 2019 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of therapeutic candidates for neurodegenerative diseases, today announced initiation of dosing in a Phase 1b clinical study of...
Biotech Pulse Biotech tumbled off a steep ski slope in the last quarter, and at the December low, the Nasdaq Biotechnology Index ( IBB ) had declined -28%, while the S&P Biotech Select Index ( XBI ) a whopping -36%. But it seems biotechs were able to regain their composure at the lows an...
Eiger BioPharmaceuticals (NASDAQ: EIGR ) initiated with Outperform rating and $47 (244% upside) price target at Baird. Shares up 13% premarket. More news on: Eiger BioPharmaceuticals, Inc., Vericel Corporation, Denali Therapeutics, Inc., Healthcare stocks news, Stocks on the mo...
by Jonathan Liss Coming from a family of medical doctors, I am no stranger to sometimes pedantic conversations about the potential efficacy of a particular drug or therapeutic treatment. Not particularly adept as an investor, my father never seriously entertained the idea of using any...
News, Short Squeeze, Breakout and More Instantly...
Denali Therapeutics Inc. Company Name:
DNLI Stock Symbol:
NASDAQ Market:
Denali Therapeutics Inc. Website:
2024-07-10 22:28:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
START is a pilot program newly launched jointly by the FDA CDER and CBER divisions to further accelerate the development of novel drug and biological products for rare diseases DNL126 was selected as one of three CDER-regulated products based on eligibility criteria including the potentia...
2024-05-10 10:16:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...